1
|
Li YY, Qu XL, Ma R, Hu J, Hei Y, Xu WQ, Wu W, Ding Z, Yang XJ. [Treatment of orbital vascular malformations with intralesional bleomycin injection and N-butyl-2-cyanoacrylate glue embolization]. Zhonghua Yan Ke Za Zhi 2023; 59:37-43. [PMID: 36631056 DOI: 10.3760/cma.j.cn112142-20220424-00207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Objective: To evaluate the clinical efficacy of bleomycin lavage combined with N-butyl-2-cyanoacrylate glue embolization and resection in the treatment of orbital vascular malformations. Methods: It was a retrospective case series study. Patients with orbital vascular malformations diagnosed at the Ophthalmology Division of Chinese PLA General Hospital from January 2018 to October 2021 were included and divided into exophthalmos group and non-exophthalmos group based on whether the patients had postural exophthalmos. Intralesional bleomycin injection and N-butyl-2-cyanoacrylate glue embolization were performed. The preoperative and postoperative visual acuity, the dosages of bleomycin and isobutyl cyanoacrylate glue, pathological results, imaging findings and remission rate were recorded and analyzed. The Chi-square test, Wilcoxon signed rank analysis and Mann-Whitney U test were used for statistical analysis. Results: A total of 58 patients (58 eyes)were included, and there were 22 males (37.9%) and 36 females (62.1%). Nineteen (32.8%) patients had postural exophthalmos, and 39 (67.2%) patients did not suffer postural exophthalmos. The patient's age of the two groups was 39.0 (28.0, 54.5) years vs. 14.0 (5.7, 26.5) years, with a statistically significant difference (Z=-3.96, P<0.001). There was no significant difference in gender, eye laterality, follow-up time and the disease course between the two groups (all P>0.05). During the operation, the dosage of bleomycin was 15 000 (13 500, 15 000) U in the exophthalmos group, and 15 000 (9 000, 16 500) U in the non-exophthalmos group (Z=-0.70, P=0.944). The dosages of N-butyl-2-cyanoacrylate glue were 2.8 (1.0, 3.0) ml and 1.7 (1.0, 2.2) ml, respectively, in the two groups, with no significant difference (Z=-1.11, P=0.268). There was no visual impairment in both groups, while the visual acuity in 5 patients without postural exophthalmos was improved postoperatively. The imaging examination results showed no difference in the malformed vascular area before and after the treatment in the exophthalmos group [384.0 (329.0, 458.0) mm2 vs. 330.5 (271.6, 356.7) mm2; Z=-1.26, P=0.208], but a significantly decreased area after the treatment in the non-exophthalmos group [960.8 (822.1, 1058.3) mm2 vs. 311.6 (164.6, 361.6) mm2; Z=-2.67, P=0.008]. All patients had no obvious local or systemic adverse reactions during the follow-up. The pathology reports showed vascular malformations in all 15 specimens obtained from the exophthalmos group, as well as vascular malformations in 41.0% (16/39) of specimens and venous lymphatic malformations in 59.0% (23/39) of specimens from the non-exophthalmos group. Thirty-nine patients had complete remission (67.2%), 19 patients had partial remission (32.8%), and the effective treatment rate was 100%. Conclusion: Bleomycin lavage combined with N-butyl-2-cyanoacrylate glue embolization can achieve good therapeutic effects on orbital vascular malformations.
Collapse
Affiliation(s)
- Y Y Li
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - X L Qu
- Department of Ophthalmology, First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China
| | - R Ma
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - J Hu
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - Y Hei
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - W Q Xu
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - W Wu
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - Z Ding
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| | - X J Yang
- The Ophthalmology Division of Chinese PLA General Hospital, Beijing 100039, China
| |
Collapse
|
2
|
Pi X, Zhang S, Wang L, Li H, Hei Y, Zheng Z, Zhou L, Wu S, Jiang F, Luo L. BiVO4 photo-catalyst with controllable wettability and its improved visible light catalytic activity for degradation of 17α-Ethinylestradiol. J Taiwan Inst Chem Eng 2021. [DOI: 10.1016/j.jtice.2021.07.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Su F, Ma R, Zhang N, Li YY, Hei Y, Xu X, Yang XJ. [A case report of orbital epithelioid hemangioendothelioma]. Zhonghua Yan Ke Za Zhi 2021; 57:696-698. [PMID: 34865408 DOI: 10.3760/cma.j.cn112142-20201203-00794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
A 70-year-old male patient, who had a right upper eyelid tumor excision 4 years ago, complained of eyelid swelling and ptosis for 3 months. Orbital CT and MRI showed an orbital cystic lesion with hemorrhage in the right eye. The tumor was resected under general anesthesia. The pathological diagnosis was epithelioid hemangioendothelioma. (Chin J Ophthalmol, 2021, 57:696-698).
Collapse
Affiliation(s)
- F Su
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - R Ma
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - N Zhang
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Y Y Li
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Y Hei
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - X Xu
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - X J Yang
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| |
Collapse
|
4
|
Zhang S, Meng W, Wang L, Li L, Long Y, Hei Y, Zhou L, Wu S, Zheng Z, Luo L, Jiang F. Preparation of Nano-Copper Sulfide and Its Adsorption Properties for 17α-Ethynyl Estradiol. Nanoscale Res Lett 2020; 15:48. [PMID: 32088775 PMCID: PMC7036085 DOI: 10.1186/s11671-020-3274-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 02/04/2020] [Indexed: 05/03/2023]
Abstract
In the present work, a tubular nano-copper sulfide was successfully synthesized by hydrothermal method. The physical and chemical properties of the prepared materials were characterized by XRD, SEM, TEM, and BET. The synthesized copper sulfide was used as an adsorbent for removing 17α-ethynyl estradiol (EE2) and exhibited excellent adsorption properties. At 25 °C, 15 mg of adsorbent was applied for 50 mL of 5 mg/L EE2 solution, adsorption equilibrium was reached after 180 min, and the adsorption rate reached nearly 90%. In addition, the kinetics, isothermal adsorption, and thermodynamics of the adsorption process were discussed on the basis of theoretical calculations and experimental results. The theoretical maximum adsorption capacity of copper sulfide was calculated to be 147.06 mg/g. The results of this study indicated that copper sulfide was a stable and efficient adsorbent with promising practical applications.
Collapse
Affiliation(s)
- Sifeng Zhang
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Wenxiang Meng
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Lulu Wang
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Lingxin Li
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Yanju Long
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Yunrui Hei
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Luting Zhou
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Shenglan Wu
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Ziguang Zheng
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China
| | - Lijun Luo
- School of Chemistry and Environment, Yunnan Minzu University, Kunming, 650500, China
| | - Fengzhi Jiang
- School of Chemical Science and Technology, Yunnan University, Kunming, 650091, China.
| |
Collapse
|
5
|
Wu X, Zhu J, Yin R, Yang J, Wu L, Liu J, Liu Z, Wang J, Gao Y, Wang D, Lou G, Yang H, Kong B, Huang Y, Zhou Q, Wen H, Hou J, Zhang C, Hei Y. A prospective evaluation of tolerability of niraparib dosing based on baseline body weight (BW) and platelet (plt) count: Blinded pooled interim safety data from the NORA study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Long Q, Hei Y, Luo Q, Tian Y, Yang J, Li J, Wei L, Liu W. BMSCs transplantation improves cognitive impairment via up-regulation of hippocampal GABAergic system in a rat model of chronic cerebral hypoperfusion. Neuroscience 2015; 311:464-73. [DOI: 10.1016/j.neuroscience.2015.10.055] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2015] [Revised: 10/26/2015] [Accepted: 10/29/2015] [Indexed: 02/06/2023]
|
7
|
Wei M, Sun Y, Liu G, Hei Y, Zhao Z. Treatments Prior to and Post Percutaneous Coronary Intervention (PCI) in China. Value Health 2014; 17:A720. [PMID: 27202549 DOI: 10.1016/j.jval.2014.08.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- M Wei
- The 6th People's Hospital of Shanghai, Shanghai, China
| | - Y Sun
- Peking University, Beijing, China
| | - G Liu
- Guanghua School of Management, Peking University, Beijing, China
| | - Y Hei
- Amgen, Inc, Thousand Oaks, CA, USA
| | - Z Zhao
- Amgen Inc, Thousand Oaks, CA, USA
| |
Collapse
|
8
|
Wei M, Sun Y, Liu G, Hei Y, Zhao Z. Lipid Control After Percutaneous Coronary Intervention (PCI) in China. Value Health 2014; 17:A764-A765. [PMID: 27202803 DOI: 10.1016/j.jval.2014.08.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- M Wei
- The 6th People's Hospital of Shanghai, Shanghai, China
| | - Y Sun
- Peking University, Beijing, China
| | - G Liu
- Guanghua School of Management, Peking University, Beijing, China
| | - Y Hei
- Amgen, Inc, Thousand Oaks, CA, USA
| | - Z Zhao
- Amgen Inc, Thousand Oaks, CA, USA
| |
Collapse
|
9
|
Shen L, Peng Z, Li Z, Gao J, Lu M, Oliner K, Gong J, Hei Y, Zhou H. Evaluation of Tumor Met Expression in Chinese Patients (Pts) with Advanced Gastric or Gastroesophageal Junction (G/Gej) Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23:2834-2842. [PMID: 22700995 DOI: 10.1093/annonc/mds142] [Citation(s) in RCA: 142] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer. PATIENTS AND METHODS Patients with a previously untreated metastatic pancreatic adenocarcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 were randomized 1 : 1 : 1 to i.v. gemcitabine 1000 mg/m(2) (days 1, 8, and 15 of each 28-day cycle) combined with open-label ganitumab (12 mg/kg every 2 weeks [Q2W]), double-blind conatumumab (10 mg/kg Q2W), or double-blind placebo Q2W. The primary end point was 6-month survival rate. Results In total, 125 patients were randomized. The 6-month survival rates were 57% (95% CI 41-70) in the ganitumab arm, 59% (42-73) in the conatumumab arm, and 50% (33-64) in the placebo arm. The grade ≥3 adverse events in the ganitumab, conatumumab, and placebo arms, respectively, included neutropenia (18/22/13%), thrombocytopenia (15/17/8%), fatigue (13/12/5%), alanine aminotransferase increase (15/5/8%), and hyperglycemia (18/2/3%). CONCLUSIONS Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6-month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6-month survival rate.
Collapse
Affiliation(s)
- H L Kindler
- Section of Hematology/Oncology, University of Chicago Medical Center, Chicago.
| | | | | | - E B Garon
- David Geffen School of Medicine at University of California Los Angeles/Translational Oncology Research International Network, Los Angeles
| | - J J Stephenson
- Department of Experimental Therapeutics, Greenville Hospital System University Medical Center, Greenville
| | - C M Rocha-Lima
- Department of Medicine, University of Miami/Sylvester Comprehensive Cancer Center, Miami
| | - H Safran
- The Brown University Oncology Group, Rhode Island Hospital, Providence
| | - D Chan
- Cancer Care Associates Medical Group, Inc., Redondo Beach
| | - D M Kocs
- US Oncology Research, Round Rock
| | - F Galimi
- Global Development, Amgen Inc., Thousand Oaks
| | - J McGreivy
- Global Development, Amgen Inc., South San Francisco, USA
| | - S L Bray
- Department of Biostatistics and Epidemiology, Amgen Ltd, Cambridge, UK
| | - Y Hei
- Global Development, Amgen Inc., Thousand Oaks
| | - E G Feigal
- Global Development, Amgen Inc., Thousand Oaks
| | - E Loh
- Global Development, Amgen Inc., South San Francisco, USA
| | - C S Fuchs
- Department of Medical Oncology/Solid Tumor Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
11
|
Bass MB, Davis MT, Kivman L, Khoo H, Notari K, Blumenschein GR, Mackey JR, Sherman SI, Hei Y, Patterson SD. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Blackhall FH, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Yang X, Smethurst D, Hei Y, Soria J. A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7534] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Patterson SD, Davis MT, Mackey JR, Martin M, Hei Y, Bass MB. Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1048] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Claret L, Lu J, Bruno R, Sikorski RS, Hei Y, Sun Y. Simulation of phase III studies of motesanib 125 mg once daily (QD) plus carboplatin/paclitaxel (CPM) or bevacizumab plus carboplatin/paclitaxel (CPB) versus carboplatin/paclitaxel (CP) in first-line non-small cell lung cancer (NSCLC) using a public domain drug–disease modeling framework and phase II data. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Cetin K, Ettinger DS, Hei Y, O'Malley CD. Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988–2003). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11053 Background: Representing roughly 85% of all lung cancers, NSCLC is frequently diagnosed at an advanced stage and has a poor prognosis. To better understand the prognostic importance of select patient and tumor characteristics in late-stage disease, we examined survival in patients diagnosed with stage IV NSCLC. Methods: Data from SEER were used to study 53,319 patients with stage IV NSCLC diagnosed between 1988 and 2003, with follow-up through 2005. The distribution of cases according to time period of diagnosis and select patient and tumor characteristics was described for each histologic subtype (squamous; adenocarcinoma (bronchioloalveolar adenocarcinoma (BAC), non-BAC); large cell; and other/unknown). Kaplan-Meier and multivariate Cox proportional hazard models were used to examine the influence of these variables on overall survival by histologic subtype. Results: Most recent period of diagnosis (1998–2003 versus 1988–1992) conferred a survival advantage across histologic subtypes, independent of gender, age, ethnicity/race, tumor grade, and uptake of surgery/radiation. This was especially pronounced for those diagnosed with large cell tumors (adjusted hazard ratio (aHR): 0.76, 95% confidence interval (CI): 0.71–0.82). Similarly, females survived longer than males across histologic groups, particularly for those with BAC tumors (aHR: 0.77, 95% CI: 0.66–0.89). Increasing age was associated with reduced survival in all histologic subtypes except BAC, where prognosis was poorest in the youngest age group. The influence of ethnicity/race also varied with histology: compared to Whites, American Indians/Alaskan Natives with squamous tumors and Blacks with large cell tumors had a poorer prognosis, whereas Asians/Pacific Islanders with either non-BAC or large cell tumors demonstrated superior survival. Conclusions: Survival among stage IV NSCLC patients improved over the study period, which may reflect the use of third generation chemotherapy as well as better supportive care. Nonetheless, lung cancer remains a deadly disease, and the prognostic effect of demographic factors varies with histologic subtype. [Table: see text]
Collapse
Affiliation(s)
- K. Cetin
- Amgen, Inc., Thousand Oaks, CA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - D. S. Ettinger
- Amgen, Inc., Thousand Oaks, CA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - Y. Hei
- Amgen, Inc., Thousand Oaks, CA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - C. D. O'Malley
- Amgen, Inc., Thousand Oaks, CA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| |
Collapse
|
16
|
Ucar K, Tchekmedyian NS, Shrina N, Chen Y, Xie T, Hei Y. Effect of zoledronic acid (Zol) compared with placebo on overall disease and bone lesion progression in patients (pts) with bone metastases from certain solid tumors: Stratification by baseline characteristics. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18541 Background: Zol has been shown to significantly reduce the risk of skeletal complications compared with placebo in pts with bone metastases from a wide range of solid tumors including a delay of bone lesion progression in pts with renal cancer. To assess whether Zol may reduce the risk of overall disease or bone lesion progression in pts with solid tumors other than breast, non-small cell lung, and prostate cancers, we conducted a retrospective analysis of pts enrolled in a large, randomized, controlled trial. Methods: Pts treated with Zol or placebo were retrospectively stratified by baseline characteristics, including Brief Pain Inventory (BPI) composite pain score, time from initial cancer diagnosis to development of bone metastases, and duration of cancer. The relative risk (RR) of disease progression during 25 months on study was analyzed using the Cox proportional hazards model (stratified log rank). Results: Median baseline BPI pain score was 2.75, median time with cancer was 15 months, and median time to development of bone metastases was 8.5 months. In pts with a baseline BPI score ≥ 2.75 (n = 236), Zol treatment significantly reduced the RR of disease progression by 34% (hazard ratio [HR] = 0.657; P = .014) and the RR of bone lesion progression by 32% (HR = 0.680; P = .028) compared with placebo. Additionally, in pts with cancer duration <15 months (n = 193), Zol treatment reduced the RR of disease progression by 45% (HR = 0.547; P = .002) and the RR of bone lesion progression by 40% (HR = 0.605; P = .016) compared with placebo. Similarly, among pts who developed bone metastases < 8.5 months from initial diagnosis of cancer (n = 193), Zol treatment significantly reduced the RR of disease progression by 39% and the RR of bone lesion progression by 48% compared with placebo (HR = 0.611; P = .009 and HR = 0.519; P = .004, respectively). Conclusions: This exploratory analysis suggests that Zol has potential antitumor effects that may reduce the risk of overall disease and bone lesion progression in pts who have higher pain scores and shorter time to development of bone metastases. Prospective studies are needed to confirm this result. [Table: see text]
Collapse
Affiliation(s)
- K. Ucar
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| | - N. S. Tchekmedyian
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| | - N. Shrina
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| | - Y. Chen
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| | - T. Xie
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| | - Y. Hei
- Pacific Shores Medical Group, Long Beach, CA; Novartis Oncology, East Hanover, NJ; Brightech International, Berkeley Heights, NJ
| |
Collapse
|
17
|
Hei Y, Lipton A, Shirina N, Chen YM, Xie T. Effect of zoledronic acid (Zol) compared with pamidronate (Pam) on disease progression in breast cancer (BC) patients with bone metastases stratified by baseline characteristics. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
678 Background: Zol has been shown to significantly reduce the risk of skeletal complications compared with Pam in BC pts with bone metastases. Zol has also demonstrated antitumor effects in animal models of human BC and significantly delayed bone lesion progression in pts with renal cancer. To assess whether Zol may reduce the risk of overall disease progression compared with Pam, we conducted a retrospective analysis of BC pts enrolled in a large randomized, controlled trial. Methods: Patients treated with Zol or Pam were retrospectively stratified by baseline characteristics, including Brief Pain Inventory (BPI) composite pain score, time from initial cancer diagnosis to development of bone metastases, and duration of cancer. The relative risk of overall disease progression during 25 months on study was analyzed using the Cox proportional hazards model. Results: Median BPI pain score at baseline was 2.75, median time to development of bone metastases was 44 months, and median time with cancer was 58 months for all patients. In the subset of pts with a baseline BPI score ≥ 2.75 (n = 556), treatment with Zol significantly reduced the risk of disease progression by 21% compared with Pam (hazard ratio [HR] = 0.793; P = .018). Similarly, among pts who developed bone metastases < 44 months from initial diagnosis of cancer (n = 564) and pts with cancer for < 58 months (n = 563), treatment with Zol reduced the risk of disease progression by approximately 20% compared with Pam (HR = 0.805; P = .026 and HR = 0.800; P = .023, respectively). Conclusions: Zol significantly reduced the risk of overall disease progression compared to Pam in specific subsets of pts with higher pain scores and shorter time to development of bone metastases. This exploratory analysis suggests that Zol has potential antitumor effects that may reduce the risk of disease progression in this patient population. These results are consistent with published reports and provide the initiative for further investigations with additional clinical studies. [Table: see text]
Collapse
Affiliation(s)
- Y. Hei
- Novartis Oncology, East Hanover, NJ; M.S. Hershey Medical Center, Hershey, PA; Brightech International, Berkeley Heights, NJ
| | - A. Lipton
- Novartis Oncology, East Hanover, NJ; M.S. Hershey Medical Center, Hershey, PA; Brightech International, Berkeley Heights, NJ
| | - N. Shirina
- Novartis Oncology, East Hanover, NJ; M.S. Hershey Medical Center, Hershey, PA; Brightech International, Berkeley Heights, NJ
| | - Y. M. Chen
- Novartis Oncology, East Hanover, NJ; M.S. Hershey Medical Center, Hershey, PA; Brightech International, Berkeley Heights, NJ
| | - T. Xie
- Novartis Oncology, East Hanover, NJ; M.S. Hershey Medical Center, Hershey, PA; Brightech International, Berkeley Heights, NJ
| |
Collapse
|
18
|
Barghout V, Abetz L, Arbuckle R, Bosch V, Hei Y, Saad F. Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14544] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14544 Background: Z has demonstrated efficacy in reducing, preventing, delaying the occurrence of an SRE (Skeletal Related Event) including pathologic fractures, severe bone pain requiring radiation therapy, spinal cord compression, surgery to bone and hypercalcemia of malignancy which could lead to a loss of independence. Effects of Z on pain were analyzed in a subgroup of patients based on performance status. Methods: Subjects were randomised to Z 4mg (n = 201) or placebo (n = 201). The short form of the Brief Pain Inventory (BPI) was administered at baseline (visit 2), and visits 3 (weeks 3–4), 4 (weeks 6–8), and then every second visit (every 6 weeks) until study end. Changes in BPI individual item scores and the Pain severity and Pain Interference scale scores were compared between Z and placebo groups. Post baseline missing data were replaced by Last Observation carried forward (LOCF). Changes in scores were examined in the subgroup of patients with ECOG performance status scores of ≥ 1. Results: For patients ECOG score of ≥ 1 at baseline (n = 227), Z was superior to placebo in the BPI items ‘pain at its worst’, ‘pain at its least’, ‘pain on average’, and the Pain Severity scale at visit 4 (weeks 6–8) and visit 6 (week 12) (p < 0.05). At visit 8 (weeks 18–20) Z was superior to placebo on the ‘pain on average’ item and Pain Severity scale (p < 0.05). For visit 12 (weeks 30–32) and for LOCF Z was superior to placebo for ‘pain at its worst’, ‘pain on average’ and Pain Severity (p < 0.05 for all). For the ‘pain right now’ item there were statistically significant differences at visits 4, 6, 12 and LOCF (p < 0.05). In addition, at visit 6 (week 12), Z was superior to placebo for changes in items assessing interference with: sleep, general activities, mood, walking and enjoyment of life (p < 0.05). Z was also superior to placebo for ‘interference with general activities’ at visits 12 (weeks 30–32), 16 (weeks 42–44) and LOCF (p < 0.05). Conclusion: Results suggest Z provides significant benefit in pain reduction and Z may have an impact on patients’ daily activities which may lead to a preservation of patients’ functionality. [Table: see text]
Collapse
Affiliation(s)
- V. Barghout
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| | - L. Abetz
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| | - R. Arbuckle
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| | - V. Bosch
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| | - Y. Hei
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| | - F. Saad
- Novartis, East Hanover, NJ; Mapi Values, Bollington, United Kingdom; Mapi Values, Lyon, France; Novartis, Florham Park, NJ; Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada
| |
Collapse
|
19
|
Affiliation(s)
- A. Lipton
- The Milton S. Hershey Medcl Ctr, Hershey, PA; Novartis Pharmaceuticals, East Hanover, NJ; Univ of Sheffield, Sheffield, United Kingdom; Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Univ of Waterloo, Waterloo, ON, Canada
| | - Y. Hei
- The Milton S. Hershey Medcl Ctr, Hershey, PA; Novartis Pharmaceuticals, East Hanover, NJ; Univ of Sheffield, Sheffield, United Kingdom; Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Univ of Waterloo, Waterloo, ON, Canada
| | - R. Coleman
- The Milton S. Hershey Medcl Ctr, Hershey, PA; Novartis Pharmaceuticals, East Hanover, NJ; Univ of Sheffield, Sheffield, United Kingdom; Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Univ of Waterloo, Waterloo, ON, Canada
| | - P. Major
- The Milton S. Hershey Medcl Ctr, Hershey, PA; Novartis Pharmaceuticals, East Hanover, NJ; Univ of Sheffield, Sheffield, United Kingdom; Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Univ of Waterloo, Waterloo, ON, Canada
| | - R. Cook
- The Milton S. Hershey Medcl Ctr, Hershey, PA; Novartis Pharmaceuticals, East Hanover, NJ; Univ of Sheffield, Sheffield, United Kingdom; Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Univ of Waterloo, Waterloo, ON, Canada
| |
Collapse
|
20
|
Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Apffelstaedt J, Hussein M, Hei Y, Coleman R. P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Breast 2005. [DOI: 10.1016/s0960-9776(05)80140-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
21
|
Guo Q, Hei Y, Chen Y. [The significance of the postburn expression of proto -- oncogenes c -- fos and c -- myc mRNA and proteins in rat myocardial cells]. Zhonghua Shao Shang Za Zhi 2001; 17:42-5. [PMID: 11876911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
OBJECTIVE To investigate the postburn expression of proto -- oncogenes c -- fos and c -- myc mRNA and proteins in rat myocardial cells following severe burn. METHODS Wistar rats inflicted with 30% TBSA III degree burn on the back were employed as the model and randomly divided into four groups: burn (B), resuscitation (R), verapamil (V) and control (C) groups. The expressions of c -- fos and c -- myc mRNA were examined by in situ hybridization and that of the proteins by immunohistochemistry. RESULTS The expressions of the proteins and mRNA of c -- fos and c -- myc in every experimental groups increased to peak values and then decreased along with time lapsing. And the expressions of c -- fos and c -- myc were weakest in B group, while that in V group was stronger than that in R group. CONCLUSION The expression of postburn immediate -- early genes c -- fos and c -- myc could be induced in the myocardial cells in all the groups by severe burns. And the expression features were different from the gene expression in patients with myocardial infarction and with cardiac over -- load. This implied that there were different signal transduction and modulation mechanism among these pathological conditions.
Collapse
Affiliation(s)
- Q Guo
- Institute of Pathology, Southwestern Hos pital, The Third Military Medical University, Chongqing 400038, P.R. China
| | | | | |
Collapse
|